SCHEMBL7717207

SCHEMBL7717207

CC/C=C/OCc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.46
AGXT P21549 3/20 0.45
TSHR P16473 2/20 0.44
TP53 P04637 1/20 0.41
ALDH1A1 P00352 2/20 0.39
MAOB P27338 2/20 0.39
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
LMNA P02545 1/20 0.35
CYP1A2 P05177 1/20 0.35
PTGS1 P23219 1/20 0.35
SLC6A2 P23975 1/20 0.35
CYP2C19 P33261 1/20 0.35
PTGS2 P35354 1/20 0.35
SLC6A3 Q01959 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7717208 1.00 IDO1 (0.46) IDO1AGXTTSHRTP53ALDH1A1
SCHEMBL6506525 0.84 IDO1 (0.43) IDO1AGXTTSHRTP53ALDH1A1
SCHEMBL27509183 0.82 TSHR (0.57) IDO1AGXTTSHRALDH1A1MAOB
SCHEMBL1068376 0.81 IDO1 (0.41) IDO1AGXTTSHRALDH1A1MAPK1
SCHEMBL1068374 0.81 IDO1 (0.41) IDO1AGXTTSHRALDH1A1MAPK1
SCHEMBL17269304 0.81 MAOB (0.58) IDO1AGXTTSHRALDH1A1MAOB
SCHEMBL20750998 0.80 TSHR (0.38) IDO1AGXTTSHRALDH1A1MAOB
SCHEMBL23553983 0.79 IDO1 (0.36) IDO1AGXTTSHRTP53ALDH1A1
SCHEMBL738243 0.79 IDO1 (0.46) IDO1AGXTTSHRALDH1A1MAOB
SCHEMBL1257815 0.79 IDO1 (0.46) IDO1AGXTTSHRALDH1A1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10195189-B2 2-phenethenyltetrahydro isoquinolines useful as anti-HIV compounds Prosetta Antiviral, Inc. (US) 2019-02-05 US disclosed
WO-2017132463-A1 SURFACE PRIMER COMPOSITIONS AND METHODS OF USE ACatechol, Inc. (US) 2017-08-03 WO disclosed
US-20020037534-A1 Combinatorial preparation of a substance library with removal of a zwitterionic compound by precipitation BASF AKTIENGESELLSCHAFT (DE) 2002-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037534-A1 Combinatorial preparation of a substance library with removal of a zwitterionic compound by precipitation NEFM, PSPH, NGLY1 IDO1 3207/4885AGXT 2815/4885TSHR 3420/4885
US-10195189-B2 2-phenethenyltetrahydro isoquinolines useful as anti-HIV compounds MAVS, EIF2AK2, POLRMT IDO1 135/4885AGXT 4118/4885TSHR 4860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.